Skip to Content
Merck
  • Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models.

Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models.

Endocrinology (2014-06-01)
A S L Caldwell, L J Middleton, M Jimenez, R Desai, A C McMahon, C M Allan, D J Handelsman, K A Walters
ABSTRACT

Polycystic ovary syndrome (PCOS) affects 5-10% of women of reproductive age, causing a range of reproductive, metabolic and endocrine defects including anovulation, infertility, hyperandrogenism, obesity, hyperinsulinism, and an increased risk of type 2 diabetes and cardiovascular disease. Hyperandrogenism is the most consistent feature of PCOS, but its etiology remains unknown, and ethical and logistic constraints limit definitive experimentation in humans to determine mechanisms involved. In this study, we provide the first comprehensive characterization of reproductive, endocrine, and metabolic PCOS traits in 4 distinct murine models of hyperandrogenism, comprising prenatal dihydrotestosterone (DHT, potent nonaromatizable androgen) treatment during days 16-18 of gestation, or long-term treatment (90 days from 21 days of age) with DHT, dehydroepiandrosterone (DHEA), or letrozole (aromatase inhibitor). Prenatal DHT-treated mature mice exhibited irregular estrous cycles, oligo-ovulation, reduced preantral follicle health, hepatic steatosis, and adipocyte hypertrophy, but lacked overall changes in body-fat composition. Long-term DHT treatment induced polycystic ovaries displaying unhealthy antral follicles (degenerate oocyte and/or > 10% pyknotic granulosa cells), as well as anovulation and acyclicity in mature (16-week-old) females. Long-term DHT also increased body and fat pad weights and induced adipocyte hypertrophy and hypercholesterolemia. Long-term letrozole-treated mice exhibited absent or irregular cycles, oligo-ovulation, polycystic ovaries containing hemorrhagic cysts atypical of PCOS, and displayed no metabolic features of PCOS. Long-term dehydroepiandrosterone treatment produced no PCOS features in mature mice. Our findings reveal that long-term DHT treatment replicated a breadth of ovarian, endocrine, and metabolic features of human PCOS and provides the best mouse model for experimental studies of PCOS pathogenesis.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Cholesterol, from lanolin, ≥99.0% (GC)
Sigma-Aldrich
Letrozole, ≥98% (HPLC)
Sigma-Aldrich
Cholesterol, tested according to Ph. Eur.
Sigma-Aldrich
SyntheChol® NS0 Supplement, 500 ×, synthetic cholesterol, animal component-free, aqueous solution, sterile-filtered, suitable for cell culture
Supelco
Cholesterol solution, certified reference material, 10 mg/mL in chloroform
Sigma-Aldrich
Luteinizing Hormone from equine pituitary, pkg of ~15 units/vial
Sigma-Aldrich
Cholesterol, powder, BioReagent, suitable for cell culture, ≥99%
Sigma-Aldrich
Cholesterol, from sheep wool, ≥92.5% (GC), powder
Sigma-Aldrich
Follicle Stimulating Hormone from human pituitary, ~7,000 IU/mg (powder)
Sigma-Aldrich
trans-Dehydroandrosterone, ≥99%
Sigma-Aldrich
Cholesterol, Sigma Grade, ≥99%
Supelco
Cholesterol, Pharmaceutical Secondary Standard; Certified Reference Material
SAFC
Cholesterol, from sheep wool, Controlled origin, meets USP/NF testing specifications
Supelco
Letrozole, Pharmaceutical Secondary Standard; Certified Reference Material
Letrozole, European Pharmacopoeia (EP) Reference Standard
SAFC
Cholesterol, Plant-Derived, SyntheChol®